Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2023-03-14 Share Issue/Capital Cha…
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
Appendix 3G and Appendix 3H 22 pages 432.9KB
Share Issue/Capital Change Classification · 95% confidence The document is an Appendix 3G form filed with the ASX, titled 'Notification of issue, conversion or payment up of unquoted equity securities.' It details the issuance of unquoted securities by Mesoblast Ltd, including dates and references to previous announcements (Appendix 3B). The content is regulatory in nature, focused on notifying the market and ASX about securities issuance events rather than providing financial results, management commentary, or detailed financial statements. It is not an annual report, earnings release, or management report. It is also not a proxy, voting result, or remuneration report. The document is a formal regulatory announcement about capital changes (issuance of securities). Therefore, it fits best under the category 'Share Issue/Capital Change' (SHA). The document length and detail confirm it is a full notification rather than a brief announcement or certification, supporting a high confidence score.
2023-03-14 English
6-K
Regulatory Filings
2023-03-08 English
Pause in Trading 1 page 109.5KB
Regulatory Filings Classification · 95% confidence The document is a brief market release announcing a temporary pause in trading of the company's securities. It is very short (321 characters) and does not contain any financial data, report content, or detailed information. It is an announcement related to trading status rather than a financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-03-07 English
FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L 4 pages 189.9KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing that the FDA has accepted the resubmission of a Biologics License Application (BLA) for a drug candidate, remestemcel-L, with a set goal date for FDA decision. It provides detailed clinical data summaries, regulatory designations (Fast Track, Priority Review), and background on the drug and disease. The document is not a full financial report, audit, or earnings release. It is not a transcript, management or governance report, or a voting or capital structure announcement. It is a regulatory update about a drug approval process and clinical data submission to the FDA. The document is lengthy (over 13,000 characters) and contains substantive information about the regulatory status and clinical data, but it is primarily a corporate announcement about regulatory progress rather than a formal regulatory filing or financial report. Given the nature of the content and the absence of financial statements or earnings data, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-03-07 English
Prospectus for Warrants Related to Oaktree Facility 46 pages 528.6KB
Capital/Financing Update Classification · 100% confidence The document is titled as a 'Prospectus for Issue of Warrants' related to an extension of a debt facility. It details the offer of warrants to investors, including terms, risk factors, and legal notices. It is a formal offering document prepared under the Corporations Act and lodged with ASIC. The content focuses on the issuance of securities (warrants) and related capital raising activities. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is not an annual report, earnings release, or other financial report type, nor is it a regulatory filing or announcement of a report. It is a full prospectus related to a financing event.
2023-03-02 English
6-K
Regulatory Filings
2023-02-28 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.